Open AccessTHE PLACE OF FOSINOPRIL IN EVIDENCE-BASED TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION
Author(s) -
С. А. Бернс,
R. I. Stryuk
Publication year - 2017
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2017-7-17-19
Subject(s) - fosinopril , medicine , population , cardiology , blood pressure , environmental health , angiotensin converting enzyme
Cardiovascular diseases (CVD) remain the main cause of mortality in the world. [1] At the same time, arterial hypertension (AH) is one of the most common CV pathologies, which, according to foreign researchers, affects about 30–45% of the general population [2] and about 40–47% of the population according to Russian studies. [3] The experts forecast that by 2030 the prevalence of hypertension will increase by approximately 10%. [4]